Skip to main content

Market Overview

Amgen Shares Could Gain $2-$4 As Competitor Coherus Receives CRL

Amgen Shares Could Gain $2-$4 As Competitor Coherus Receives CRL

Can one man's pain be another man's gain? It seems so. Even within the stock market, this phenomenon is present, seen through sympathy moves, which result in stocks belonging to the same sector/industry or having the same category of products moving either in tandem with each other or in opposite directions.

Such a move is likely to be seen within the biotech sector, according to an analyst who predicts Amgen, Inc. (NASDAQ: AMGN) will move higher following a regulatory setback by competitor Coherus Biosciences Inc (NASDAQ: CHRS).

The CRL That Knocked Coherus Off

Coherus fell close to 24 percent Monday after it announced that the FDA has issued it a complete response letter for its aBLA for its CHS-1701, a pegfilgrastim biosimilar candidate to Amgen's Neulasta.

This product worth $4 billion per year for Amgen fell off the patent cliff in 2015. With other biosimilar candidates to Neulasta being unsuccessful in clearing the regulatory hurdle, it looks like Amgen is the winner all the way.

Even if the FDA vets the aBLAs of competing drug makers they face the prospect of contending with Amgen on the grounds of patent infringement.

Amgen Shows Very Little Reaction

Despite the negative news for Coherus being positive for Amgen, the shares of the latter reacted with only a modest move to the upside. Amgen shares rose 0.50 percent to $164.88 on Monday.

It is against this backdrop that Street chatter quoting Mizuho Securities said investors were bracing for CHS-1701 entry in the second half of 2017. The firm believes the denial pushed out the erosion curve by 12–18 months, depending on when Coherus refiles its aBLA and whether the FDA classifies the resubmission as Class 1 or 2.

If the FDA classifies the resubmission as Class 1, the review will be completed in two months, but a Class 2 status would mean a lengthier review period of 6 months.

Specifically, Mizuha sees $2 to $4 upside to Amgen shares on the Coherus news.

At last check, shares of Coherus were up 5.25 percent at $16.55.

Related Links:

Tracking The Busy June PDUFA Calendar

Meet This Week's IPOs: A Biotech, A BDC And A Builder

Latest Ratings for AMGN

Apr 2021OppenheimerMaintainsOutperform
Mar 2021BarclaysMaintainsEqual-Weight
Mar 2021Morgan StanleyMaintainsOverweight

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings


Related Articles (AMGN + CHRS)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Education Health Care Analyst Ratings Movers Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at